261 related articles for article (PubMed ID: 35418149)
1. EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectives.
Hou J; Li H; Ma S; He Z; Yang S; Hao L; Zhou H; Zhang Z; Han J; Wang L; Wang Q
Biomark Res; 2022 Apr; 10(1):21. PubMed ID: 35418149
[TBL] [Abstract][Full Text] [Related]
2. Current status and breakthroughs in treating advanced non-small cell lung cancer with EGFR exon 20 insertion mutations.
Hu M; Zhong C; Wang J; Chen J; Zhou T
Front Immunol; 2024; 15():1399975. PubMed ID: 38774882
[TBL] [Abstract][Full Text] [Related]
3. EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study.
Yang G; Li J; Xu H; Yang Y; Yang L; Xu F; Xia B; Zhu VW; Nagasaka M; Yang Y; Li Y; Qiu W; Ying J; Ou SI; Wang Y
Lung Cancer; 2020 Jul; 145():186-194. PubMed ID: 32336530
[TBL] [Abstract][Full Text] [Related]
4. EGFR exon 20 insertion mutations in non-small cell lung cancer.
Wang F; Li C; Wu Q; Lu H
Transl Cancer Res; 2020 Apr; 9(4):2982-2991. PubMed ID: 35117654
[TBL] [Abstract][Full Text] [Related]
5. EGFR exon20 insertion mutations in non-small cell lung cancer: Clinical implications and recent advances in targeted therapies.
Bai Q; Wang J; Zhou X
Cancer Treat Rev; 2023 Nov; 120():102605. PubMed ID: 37703723
[TBL] [Abstract][Full Text] [Related]
6. Emerging therapies for non-small cell lung cancer harboring EGFR exon 20 insertion mutations: narrative review.
Watanabe N; Horio Y; Fujiwara Y
Ann Transl Med; 2022 Dec; 10(23):1283. PubMed ID: 36618815
[TBL] [Abstract][Full Text] [Related]
7. Immune microenvironment features and efficacy of PD-1/PD-L1 blockade in non-small cell lung cancer patients with EGFR or HER2 exon 20 insertions.
Chen K; Pan G; Cheng G; Zhang F; Xu Y; Huang Z; Fan Y
Thorac Cancer; 2021 Jan; 12(2):218-226. PubMed ID: 33210451
[TBL] [Abstract][Full Text] [Related]
8. EGFR exon 20 Insertion NSCLC and Response to Platinum-Based Chemotherapy.
Shah MP; Aredo JV; Padda SK; Ramchandran KJ; Wakelee HA; Das MS; Neal JW
Clin Lung Cancer; 2022 Mar; 23(2):e148-e153. PubMed ID: 34391686
[TBL] [Abstract][Full Text] [Related]
9. Long-term survival after stereotactic body radiotherapy combined with immunotherapy plus anti-angiogenesis therapy in patients with advanced non-small cell lung cancer and
Luo Q; Chen L; Li Z; Cheng L; Zhang S; Zong Y; Li Q; Suda K; Santarpia M; Dalia S; Meng R
Transl Lung Cancer Res; 2023 Nov; 12(11):2330-2341. PubMed ID: 38090524
[TBL] [Abstract][Full Text] [Related]
10. [Advances in the Treatment of EGFR Exon 20ins Mutant NSCLC].
Xu M; Luo J; Xu R
Zhongguo Fei Ai Za Zhi; 2023 Feb; 26(2):151-157. PubMed ID: 36872053
[TBL] [Abstract][Full Text] [Related]
11. Impact of EGFR amplification on survival of patients with EGFR exon 20 insertion-positive non-small cell lung cancer.
Gao X; Wei XW; Zheng MY; Chen ZH; Zhang XC; Zhong WZ; Yang JJ; Wu YL; Zhou Q
J Thorac Dis; 2020 Oct; 12(10):5822-5832. PubMed ID: 33209414
[TBL] [Abstract][Full Text] [Related]
12. Tumor genomics and response to chemotherapy in advanced non-small cell lung cancer with exon 20 insertion epidermal growth factor receptor mutations.
Wang Y; Li J; Zhou Y; Cao S; Ling X; Zhang Y; Nie W; Zhong H
Ann Transl Med; 2020 Oct; 8(20):1297. PubMed ID: 33209877
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of Treatments for Advanced Non-Small-Cell Lung Cancer With Exon 20 Insertion Epidermal Growth Factor Receptor Mutations.
Wu JY; Yu CJ; Shih JY
Clin Lung Cancer; 2019 Nov; 20(6):e620-e630. PubMed ID: 31327643
[TBL] [Abstract][Full Text] [Related]
14. [Progress in Detection of EGFR Exon 20 Insertion Mutation and Targeted Therapies
in Non-small Cell Lung Cancer].
Wang Y; Chu T
Zhongguo Fei Ai Za Zhi; 2023 Feb; 26(2):135-147. PubMed ID: 36872052
[TBL] [Abstract][Full Text] [Related]
15. Tackling Drug Resistance in EGFR Exon 20 Insertion Mutant Lung Cancer.
Pacini L; Jenks AD; Vyse S; Wilding CP; Arthur A; Huang PH
Pharmgenomics Pers Med; 2021; 14():301-317. PubMed ID: 33727854
[TBL] [Abstract][Full Text] [Related]
16. Case report: sequential use of almonertinib based on the
Wang R; Yu S; Yu L; Zhao J; Jiao S; Wang Q; Wu Y
Transl Cancer Res; 2022 Jun; 11(6):1836-1843. PubMed ID: 35836508
[TBL] [Abstract][Full Text] [Related]
17. Response to Afatinib in a Patient with NSCLC Harboring Novel
Lin L; Wu X; Yan S; Zhu Y; Yan Z; Lv D; Ge H
Onco Targets Ther; 2020; 13():9753-9757. PubMed ID: 33061454
[TBL] [Abstract][Full Text] [Related]
18. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
Gelatti ACZ; Drilon A; Santini FC
Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
[TBL] [Abstract][Full Text] [Related]
19. Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed after platinum-based chemotherapy.
Minchom A; Viteri S; Bazhenova L; Gadgeel SM; Ou SI; Trigo J; Bauml JM; Backenroth D; Bhattacharya A; Li T; Mahadevia P; Girard N
Lung Cancer; 2022 Jun; 168():74-82. PubMed ID: 35597172
[TBL] [Abstract][Full Text] [Related]
20. Osimertinib for Chinese advanced non-small cell lung cancer patients harboring diverse EGFR exon 20 insertion mutations.
Yang GJ; Li J; Xu HY; Sun Y; Liu L; Li HS; Yang L; Zhang Y; Li GH; Wang Y
Lung Cancer; 2021 Feb; 152():39-48. PubMed ID: 33341538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
